NeuroSense Sets Nasdaq Hearing as Listing Deficiency Remains
Shares remain listed while NeuroSense seeks to address a market-value requirement and prepares regulatory and funding milestones for PrimeC.
Key takeaways
- The Nasdaq hearing is scheduled for November 10, and shares are expected to keep trading pending the Panel’s decision.
- NeuroSense has regained minimum bid-price compliance, but a $35 million market-value requirement remains.
NeuroSense Therapeutics said its Nasdaq hearing is scheduled for November 10, after the company appealed a delisting determination. Its shares and warrants are expected to continue trading pending the Panel’s decision.
The company has regained compliance with Nasdaq’s $1.00 minimum bid-price requirement. It said the remaining deficiency is the $35 million minimum market value of listed securities requirement. NeuroSense plans to present measures to meet that standard or the alternative $2.5 million stockholders’ equity standard.
NeuroSense is targeting December 2026 for a Health Canada New Drug Submission for PrimeC. A decision on grant funding for the Phase 3 PARAGON trial is expected in the first quarter of 2027, subject to completion of the review.
This article was produced with the help of AI technology. Source: Yahoo Finance
